Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research
Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services (www.oncodesign-services.com), a leading CRO specialized in drug discovery and preclinical services, announce the execution of a license agreement for the use of the AbYlink™ technology for preclinical services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424538240/en/
AbYlink™ is a regio-selective bioconjugation technology ideally suited for preparing conjugates for use in therapeutic and non-invasive diagnostic applications. Oncodesign Services will use this cutting-edge technology to prepare antibody chelator conjugates for use in preclinical studies to gain insights into the predictive effectiveness of novel treatment approaches in Molecular Radiotherapy, and particularly Radioimmunotherapy in the context of cancer. A joint poster will be presented at the AACR Annual Meeting 2025 to demonstrate the use of the non-invasive technology in Radioimmunotherapy, targeting animal models bearing HER2+ tumors.
“We have demonstrated the effectiveness of this powerful technology to rapidly and covalently conjugate any off-the-shelf antibody in a single step with an imaging agent. Our strategic collaboration with Oncodesign Services allows broader access to and usage of non-invasive imaging applications and provides an innovative solution to biotech and pharma partners to integrate imagery in the development of new antibody- and ADC-based therapeutics,” commented Frédéric Lévy, Chief Scientific Officer at Debiopharm.
Aidan Synnott, CEO of Oncodesign Services, said, “We are pleased to integrate this cutting-edge technology into our portfolio for our clients. The AbYlink™ technology gives the advantage of generating reproducible batches of bioconjugated antibodies and ADCs that secure specificity and efficacy of targeted radiotherapy.”
About AbYlink™
AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use to prepare diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads.
About Debiopharm Research & Manufacturing
Debiopharm Research & Manufacturing manufactures treatments for prostate cancer, breast cancer and precocious puberty, namely at its Martigny facility, where it employs two hundred people. It is a subsidiary of the pharmaceutical company Debiopharm, headquartered in Lausanne, Switzerland. Debiopharm is an innovative company, devoting over 90% of its resources to innovation and the development of new drugs. Its mission is to develop innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit: www.debiopharm.com
Follow us on LinkedIn https://www.linkedin.com/company/debiopharminternational/
About Oncodesign Services
Oncodesign Services is a contract research organization specializing in drug discovery and preclinical development. The company works with global biopharma partners to advance therapies in oncology, inflammation and infectious diseases through integrated services in protein sciences, structural biology, medicinal chemistry, pharmaco-imaging, DMPK and in vivo/in vitro pharmacology. Oncodesign Services has European facilities in France and the Netherlands.
More information on the website www.oncodesign-services.com
Follow us on LinkedIn https://www.linkedin.com/company/oncodesign/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424538240/en/
Contacts
Debiopharm Research & Manufacturing Contact:
Dawn Bonine – Head of Communications
Dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
Oncodesign Services Contact:
Nathalie Dubois – Marketing Manager
comms@oncodesign-services.com
Tel.: +33 (0)3 80 78 82 60
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aztec Group and Lantern Form a Strategic Alliance to Elevate Fund Data Access and Client Experience in Private Markets24.4.2025 12:16:00 EEST | Press release
Private markets are at a tipping point – the demand for streamlined, accessible fund data is growing rapidly, driven by General Partners (GPs) and investors who expect greater transparency, speed, and collaboration. In response, Aztec Group, a leading fund and corporate services provider, has partnered with Lantern, an innovative data intelligence platform, to enhance how clients can access high-quality, on-demand fund data and enable data-driven decision-making. Will Relf, Director of Data at Aztec commented: “As the industry continues to evolve, access to high-quality, timely data is no longer a luxury - it’s a necessity. At Aztec, we are committed to ensuring our clients can operate with confidence, backed by trusted data. Working with Lantern further enhances our ability to provide clients with innovative solutions for on-demand fund data, fully integrated with our accounting records and other key data sources.” By utilising Lantern as a component of its broader data offering, Azte
Aqualung Carbon Capture Successfully Closes Phase 1 2025 Financing Round24.4.2025 11:33:00 EEST | Press release
Aqualung Carbon Capture (“Aqualung”), a pioneering leader in membrane carbon dioxide (CO2) capture and separation technology, is excited to announce the successful first close of its funding round. This round is backed by Aqualung’s Joint Development Agreement (JDA) partner, one of the largest global membrane manufacturers, along with other strategic investors including Liquid Gas Equipment Ltd (LGE), wholly owned by Babcock International Group, Tupras Ventures, and Delek Innovation, the CVC of Delek (US) Holdings. This capital raise represents a significant milestone in Aqualung’s mission to establish itself as a leading carbon capture company. Over the past four years, Aqualung’s pilot units have successfully demonstrated its innovative non-pressurized facilitated transport membrane solution to be cost effective and applicable across various industries, including natural gas processing, lime kilns, and waste-to-energy applications. These units will continue to underpin the commercial
IQM to Deploy Poland’s First Superconducting Quantum Computer24.4.2025 11:21:00 EEST | Press release
The first quantum computer in Poland developed by IQM Quantum Computers, a global leader in superconducting quantum computers, will be operational at the Wrocław University of Science and Technology (WUST) in the second quarter of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424928607/en/ IQM Spark quantum computer This instalment of a full-stack quantum computer marks a critical milestone in the country’s technological advancement. The 5-qubit quantum computer called “IQM Spark” will enable the university to spearhead research work mainly in the field of computer science. The system will also be made available to researchers, doctoral candidates, and computer science students. Some of the first users who will run their programmes on the system are expected to be members of the qubit quantum computing club operating at the university. “This is the first quantum computer in our country and Eastern Europe using
Omdia Ranks Infobip as a Leader in the CPaaS Universe Report for the Third Time24.4.2025 11:00:00 EEST | Press release
Global communications platform Infobiphas been ranked as a leader in the Omdia CPaaS Universe report 2025. Infobip has been recognized as a leader for the third time, improving its overall ranking in 2025 compared to the previous report in 2023. Infobip’s robust Communication Platform-as-a-Service (CPaaS) services, RCS Business Messaging (RBM) campaigns, connection to the emerging Network API ecosystem, and innovation through AI and Gen AI are key factors highlighted in the Omdia report. The Omdia CPaaS Universe report is a comprehensive analysis of the CPaaS market, drawing on the firm’s forecasting and enterprise insights survey data. The report provides a forward-looking matrix of capabilities, attributes, and features that are important within the market. Omdia recognizes Infobip as a leading CPaaS provider, delivering exceptional communication services to enterprises, developers, hyperscalers, partners, and telcos. Pamela Clark-Dickson, Principal Analyst at Omdia, said: “Infobip p
World’s first Low Carbon Ratings system for Cement and Concrete launches24.4.2025 11:00:00 EEST | Press release
The Global Cement and Concrete Association (GCCA) announces the launch of Low Carbon Ratings (LCR) for Cement and Concrete - a first-of-its-kind transparent global rating system that will enable cement and concrete to be identified based on their carbon footprints. The ratings system is designed to help customers prioritise sustainability when selecting construction materials by using a clear and intuitive AA to G scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424485662/en/ GCCA Low Carbon Ratings for Cement and Concrete Inspired by well-known appraising schemes such as the EU’s Energy Performance Certificates and the US Home Energy Rating System, the LCR offers a simple, transparent, and adaptable tool that helps builders, architects, governments, planners, and consumers everywhere in the world to make more informed and sustainable choices. Thomas Guillot, Chief Executive of the GCCA, said: “Cement and concrete ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom